Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study.

ABSTRACT:

Introduction

Identifying Alzheimer's disease (AD) pharmacologic treatment options that effectively reduce the risk of mortality and hospitalization in real-world settings is critical.

Methods

We compared donepezil, galantamine, memantine, oral rivastigmine, and transdermal rivastigmine with regard to all-cause mortality and all-cause hospitalization risk among fee-for-service Medicare beneficiaries with AD (aged ≥ 65 years) using a retrospective cohort study design. Our primary analysis was based on intention to treat (ITT), but we also present as-treated analysis.

Results

In our final study sample (N = 21,558), significant difference in survival among index AD medication groups were observed with donepezil being associated with better survival than memantine, and ora

SUBMITTER: Bhattacharjee S 

PROVIDER: S-EPMC6626065 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature